Evolus, Inc.EOLSEarnings & Financial Report
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
Revenue
$69.4M
Gross Profit
$45.3M
Operating Profit
$-10.2M
Net Profit
$-17.1M
Gross Margin
65.3%
Operating Margin
-14.7%
Net Margin
-24.7%
YoY Growth
3.7%
EPS
$-0.27
Evolus, Inc. Q2 FY2025 Financial Summary
Evolus, Inc. reported revenue of $69.4M (up 3.7% YoY) for Q2 FY2025, with a net profit of $-17.1M (down 51.0% YoY) (-24.7% margin). Cost of goods sold was $24.1M, operating expenses totaled $55.5M.
Key Financial Metrics
| Total Revenue | $69.4M |
|---|---|
| Net Profit | $-17.1M |
| Gross Margin | 65.3% |
| Operating Margin | -14.7% |
| Report Period | Q2 FY2025 |
Evolus, Inc. Annual Revenue by Year
Evolus, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $297.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $297.2M |
| 2024 | $266.3M |
| 2023 | $202.1M |
| 2022 | $148.6M |
Evolus, Inc. Quarterly Revenue & Net Profit History
Evolus, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $73.1M | +6.7% | $-10.7M | -14.6% |
| Q4 FY2025 | $90.3M | +14.4% | $130.0K | 0.1% |
| Q3 FY2025 | $69.0M | +12.9% | $-15.7M | -22.8% |
| Q2 FY2025 | $69.4M | +3.7% | $-17.1M | -24.7% |
| Q1 FY2025 | $68.5M | +15.5% | $-18.9M | -27.6% |
| Q4 FY2024 | $78.9M | +29.4% | $-6.8M | -8.6% |
| Q3 FY2024 | $61.1M | +22.1% | $-19.2M | -31.4% |
| Q2 FY2024 | $66.9M | +35.6% | $-11.3M | -17.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.9M | $61.1M | $78.9M | $68.5M | $69.4M | $69.0M | $90.3M | $73.1M |
| YoY Growth | 35.6% | 22.1% | 29.4% | 15.5% | 3.7% | 12.9% | 14.4% | 6.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $233.8M | $229.6M | $232.6M | $213.4M | $228.8M | $219.0M | $225.9M | $220.6M |
| Liabilities | $214.5M | $223.7M | $227.0M | $220.0M | $247.5M | $247.8M | $249.0M | $249.4M |
| Equity | $19.3M | $5.9M | $5.5M | $-6.6M | $-18.7M | $-28.8M | $-23.1M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-6.5M | $-5.7M | $4.8M | $-15.6M | $-24.8M | $-14.7M | $12.8M |